Combined antianginal therapy based on nicorandil: feasibility and effectiveness

The article presents an analysis of the data from the current literature on the feasibility of the combined use of two antianginal drugs: the vasodilator nicorandil and the myocardial cytoprotector trimetazidine, which the European Society of Cardiology recommends for the treatment of coronary heart disease and heart failure. Different mechanisms of action, increased clinical efficacy, possible synergism of action, favorable effects on target organs, and the absence of additional side effects make this combination promising for clinical use. Future clinical trials and meta-analyses will be able to provide a definitive answer regarding the effectiveness of this combination. At the same time, preliminary data support its use to reverse endothelial dysfunction, improve left ventricle function, suppress chronic inflammation, and reduce the risk of major adverse cardiac events.

Список використаної літератури

1. Ajabnoor A., Mukhtar A. (2022) Effect of trimetazidine on the functional capacity of ischemic heart disease patients not suitable for revascularization: Meta-analysis of randomized controlled trials. PLoS One, 17(2): e0263932. doi: 10.1371/journal.pone.0263932.
2. Boden W.E., Marzilli M., Crea F. et al. (2023) Evolving Management Paradigm for Stable Ischemic Heart Disease Patients: JACC Review Topic of the Week. J. Am. Coll. Cardiol., 81(5): 505–514. doi: 10.1016/j.jacc.2022.08.814.
3. Chakraborty R. (2023) Nicorandil, Novel Potassium Adenosine Triphosphate Channel (K+ ATP) Opener in Ischemia With Non-Obstructive Coronary Arteries (INOCA) and Atherosclerotic Cardiovascular Disease (ASCVD): Delphi Consensus Statement. Cureus, 15(1): e33624. doi: 10.7759/cureus.33624.
4. Chen Z., Li S., Liu M. (2024) Nicorandil alleviates cardiac microvascular ferroptosis in diabetic cardiomyopathy: Role of the mitochondria-localized AMPK-Parkin-ACSL4 signaling pathway. Pharmacol. Res., 200: 107057. doi: 10.1016/j.phrs.2024.107057.
5. El-Khodary N.M., Ghoneim A.I., El-Tayaar A. et al. (2023) The Impact of Trimetazidine on Cardiac Fibrosis, Inflammation, and Function in Ischemic Cardiomyopathy Patients. Cardiovasc. Drugs Ther., 37(5): 955–964. doi: 10.1007/s10557-022-07340-0.
6. Geng N., Ren L., Xu L. et al. (2021) Clinical outcomes of nicorandil administration in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc. Disord., 21(1): 488. doi: 10.1186/s12872-021-02301-1.
7. Giannopoulos A., Giannoglou G., Chatzizisis Y. (2016) Pharmacological approaches of refractory angina. Pharmacol. Ther., 163: 118–131. doi: 10.1016/j.pharmthera.2016.03.008.
8. Ferrari R., Camici P., Crea F. et al. (2018) A ‘diamond’ approach to personalized treatment of angina. Nat. Rev. Cardiol., 15: 120–132. doi.org/10.1038/nrcardio.2017.131.
9. Kamisah Y., Che Hassan H. (2024) Role of Trimetazidine in Ameliorating Endothelial Dysfunction: A Review. Pharmaceuticals (Basel), 17(4): 464. doi: 10.3390/ph17040464.
10. Knuuti J., Wijns W., Saraste A. et al. (2020) ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J., 41(3): 407–477. doi: 10.1093/eurheartj/ehz425.
11. Li J., Li Y. (2020) Effects of Nicorandil combined with Trimetazidine on endothelial cell microparticles, endothelial cell-specific molecule-1 and high-Sensitivity C-reactive protein in patients with acute myocardial infarction after PCI. Int. J. Clin. Exp. Med., 13(4): 2339–2346.
12. Ping L., Juan C., Na L. et al. (2023) Real-World Major Adverse Cardiovascular Events of Nicorandil and Nitrate in Coronary Heart Disease in Central China: A Retrospective Cohort Study. Cardiol. Discovery, 3(3): 152–158. doi: 10.1097/CD9.0000000000000092.
13. Lu Y., Hu W., Song Q., Wang Q. (2020) The Efficacy and Safety of Nicorandil for Periprocedural Myocardial Injury in Patients Undergoing PCI: A Meta-Analysis. J. Interv. Cardiol., 2020: 3293587. doi: 10.1155/2020/3293587.
14. Martha J.W., Pranata R., Wibowo A. et al. (2021) The effect of trimetazidine on contrast-induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention — A systematic review and meta-analysis. Eur. Rev. Med. Pharmacol. Sci., 25(7): 3045–3053. doi: 10.26355/eurrev_202104_25558.
15. McDonagh T.A., Metra M., Adamo M. et al. (2022) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Rev. Esp. Cardiol. (Engl. Ed). 75(6): 523. doi: 10.1016/j.rec.2022.05.005.
16. Nassiri S., Van de Bovenkamp A., Remmelzwaal S. et al. (2024) Effects of trimetazidine on heart failure with reduced ejection fraction and associated clinical outcomes: a systematic review and meta-analysis. Open Heart, 11(1): e002579. doi: 10.1136/openhrt-2023-002579.
17. Pearce L., Carr R., Yellon D. et al. (2023) Nicorandil — an Effective Multitarget Drug for Cardioprotection? Cardiovasc. Drugs Ther., 37(1): 5–8. doi: 10.1007/s10557-022-07397-x.
18. Shen L., Qiu L., Liu J. et al. (2022) Clinical Implications of Nicorandil Combined with Trimetazidine in Patients with Coronary Heart Disease: A Real-World Observational Study. Adv. Ther., 39(1): 655–673. doi: 10.1007/s12325-021-01987-1.
19. Tong X., Shen L., Zhou X. et al. (2023) Comparative Efficacy of Different Drugs for the Treatment of Dilated Cardiomyopathy: A Systematic Review and Network Meta-analysis. Drugs R.D., 23(3): 197–210. doi: 10.1007/s40268-023-00435-5.
20. Virani S.S., Newby L.K., Arnold S. et al. (2023) 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation, 148(9): e9–e119. doi: 10.1161/CIR.0000000000001168.
21. Wang C., Chen W., Yu M., Yang P. (2021) Efficacy of Trimetazidine in Limiting Periprocedural Myocardial Injury in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Angiology, 72(6): 511–523. doi: 10.1177/0003319720987745.
22. Wang L., Wang W., Zhang J. et al. (2024) Effectiveness of Nicorandil with Trimetazidine with Coronary Heart Disease-Induced Chronic Heart Failure and Its Influence on Cardiac Function in Elderly. Indian J. Pharm. Sci., 86(3): 303–309.
23. Cheng W., Huang M.-E., Luo Zh.-R. (2018) The Preventive Effects of Combined Nicorandil With Trimetazidine on Contrast-induced Nephrophathy in Patients Undergoing Elective Percutaneous Coronary Intervention. Chinese Circulation J., (12): 989–994.
24. Wu Y., Fan Y., Huang N. et al. (2021) Effect of nicorandil combined with trimetazidine on miR-223-3p and NRF2 expression in patients with coronary heart disease. Am. J. Transl. Res., 13(5): 4804–4811.
25. Zhang Y., Zhao J., Ren C. et al. (2023) Free fatty acids induce coronary microvascular dysfunction via inhibition of the AMPK/KLF2/eNOS signaling pathway. Int. J. Mol. Med., 51(4): 34. doi: 10.3892/ijmm.2023.5237.
26. Zhao C., Jin C., He X., Xiang M. (2021) The efficacy of trimetazidine in non-ischemic heart failure patients: a meta-analysis of randomized controlled trials. Rev. Cardiovasc. Med., 22(4): 1451–1459. doi: 10.31083/j.rcm2204149.
27. Zhou J., Xu J., Cheng A. et al. (2020) Effect of nicorandil treatment adjunctive to percutaneous coronary intervention in patients with acute myocardial infarction: a systematic review and meta-analysis. J. Int. Med. Res., 48(11): 300060520967856. doi: 10.1177/0300060520967856.